Edward Dulac III Sells 4,677 Shares of Intellia Therapeutics (NASDAQ:NTLA) Stock

Posted by Brian Himes on Jul 8th, 2026

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) EVP Edward Dulac III sold 4,677 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the transaction, the executive vice president owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. This trade represents a 2.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Intellia Therapeutics Trading Down 2.3%

Shares of NTLA stock opened at $17.43 on Wednesday. Intellia Therapeutics, Inc. has a 12-month low of $7.95 and a 12-month high of $28.25. The business’s fifty day simple moving average is $14.25 and its 200-day simple moving average is $13.19. The company has a market cap of $2.44 billion, a PE ratio of -4.92 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The firm had revenue of $15.05 million for the quarter, compared to the consensus estimate of $13.81 million. During the same period in the previous year, the business earned ($1.10) EPS. On average, equities analysts forecast that Intellia Therapeutics, Inc. will post -3.18 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new position in shares of Intellia Therapeutics in the 3rd quarter valued at about $30,000. Advisory Services Network LLC purchased a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at approximately $33,000. Headlands Technologies LLC purchased a new stake in Intellia Therapeutics during the 2nd quarter worth approximately $26,000. Comerica Bank lifted its stake in Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after acquiring an additional 901 shares during the last quarter. Finally, Danske Bank A S purchased a new stake in Intellia Therapeutics during the third quarter worth approximately $50,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on NTLA. Truist Financial raised shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Wedbush reaffirmed a “neutral” rating and issued a $12.00 price target on shares of Intellia Therapeutics in a report on Monday, June 15th. The Goldman Sachs Group lifted their price objective on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research note on Tuesday, April 28th. Canaccord Genuity Group reissued a “buy” rating and issued a $49.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, June 16th. Finally, Citizens Jmp restated a “market outperform” rating and issued a $30.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Intellia Therapeutics has an average rating of “Hold” and a consensus target price of $20.46.

Check Out Our Latest Report on NTLA

Intellia Therapeutics Company Profile

(Get Free Report)

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.